Rubraca improves PFS in first-line maintenance treatment of ovarian cancer regardless of biomarker status in phase III ATHENA-MONO trial

Cancer clinical trials shouldn’t discriminate—but they do

In 2004, doctors told my husband Mike there was nothing more they could do—the pancreatic cancer he was diagnosed with would soon take his life.

October 11, 2024

Vol.50 No.38

By Erin Miller

In the Archives

Less Radical podcast: The origins of modern surgery, radical mastectomy, and the first randomized trials in breast cancer

Less Radical tells the story of surgeon-scientist Bernie Fisher, who revolutionized breast cancer treatment and transformed the way we understand cancer.

October 11, 2024

Vol.50 No.38

In Brief

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

Scientists at the University of Oxford are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 (approximately US$800,000) for the study over the next three years to support lab research into the vaccine.

October 04, 2024

Vol.50 No.37

Clinical Roundup

Carvykti extended OS in r/r MM vs standard therapies in phase III trial

Long-term results from the phase III CARTITUDE-4 study show a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.

October 04, 2024

Vol.50 No.37

Clinical Roundup

Crofelemer relieves diarrhea in breast cancer subgroup in phase III trial

The recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the phase III OnTarget trial indicate that crofelemer (Mytesi, Fulyzaq) achieved statistical significance in this subgroup.

October 04, 2024

Vol.50 No.37

Clinical Roundup

First-in-human study of novel inhibitor shows promise in MTAP-deleted solid tumors

AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses across patients with MTAP-deleted solid tumors, as well as an acceptable safety profile, according to first-in-human results of a dose-exploration/dose-expansion phase I study (NCT05094336) that were presented at the 2024 ESMO Congress.

October 04, 2024

Vol.50 No.37

Rubraca improves PFS in first-line maintenance treatment of ovarian cancer regardless of biomarker status in phase III ATHENA-MONO trial

YOU MAY BE INTERESTED IN

Cancer clinical trials shouldn’t discriminate—but they do

Less Radical podcast: The origins of modern surgery, radical mastectomy, and the first randomized trials in breast cancer

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

Carvykti extended OS in r/r MM vs standard therapies in phase III trial

Crofelemer relieves diarrhea in breast cancer subgroup in phase III trial

First-in-human study of novel inhibitor shows promise in MTAP-deleted solid tumors

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login